This #CME activity for gastroenterologists explores emerging therapeutic strategies targeting the TL1A pathway: https://t.co/sexdi5DAqa
@DrAllegrettiIBD
"TL1A Inhibition for IBD: Emerging Therapies at the Intersection of Inflammation and Fibrosis" is now available on GastroCE!
Earn #CME credit now: https://t.co/sexdi5DAqa
@DrAllegrettiIBD
👩⚕️Participants of "IBD Advancements: The Promise of TL1A-Targeted Therapies" will examine the role of the TL1A pathway in IBD.
Participate today >> https://t.co/O4qG76jT7m
@silvio_silvio75#GITwitter#Gastroenterology#CME
"IBD Advancements: The Promise of TL1A-Targeted Therapies" on @Gastro_CE addresses unmet needs in IBD care and examines the role of the TL1A pathway in IBD.
Participate now >> https://t.co/1nfhsaaZWm
@silvio_silvio75#GITwitter#Gastroenterology#CME
Calling all gastroenterologists 🚨
Which of these answers is correct? Test your knowledge here>> https://t.co/enBWHpZYYy
@IBDMD#GITwitter#Gastroenterology#CME#AAPA
👩⚕️Participants of "IBD Management: Mastering Recent Guideline Updates to Optimize Patient-Centered Solutions" will explore health-management strategies for patients with IBD.
Participate today >> https://t.co/enBWHpZYYy
@IBDMD#GITwitter#Gastroenterology#CME#AAPA
📣 Don't miss the recently updated guidelines for IBD management with this newly posted #CME / #AAPA activity >> https://t.co/enBWHpZYYy
@IBDMD#GITwitter#Gastroenterology
📹 This CE activity includes compelling “Doctormentary” segments that highlight the real-world eosinophilic esophagitis patient journey, interspersed with discussions on clinical decision-making.
Participate now >> https://t.co/ZLEaXO3XJp
👩⚕️Participants of "Eosinophilic Esophagitis: Empowering Clinicians for Better Patient Outcomes" will examine the expanding role of advanced therapies and explore strategies to overcome access barriers.
Participate today >> https://t.co/ZLEaXO3XJp